At the start of the New Year, Dr Carl June (@carlhjune) who needs no introduction as one of pioneers of Chimeric Antigen Receptor (CAR) T cell therapy tweeted that, “2020 will be the decade of cell therapy and genome engineering.”
So what does the next decade hold for CAR T cell therapy?
At the recent 2nd European CAR T cell meeting, jointly organized by EHA and EBMT, we asked the man himself to tell us more about his vision.
In Sitges, Dr June kindly spoke to BSB and shared his thoughts on where he sees the CAR T field going, some of the key challenges that will need to be overcome, as well as some of the opportunities to watch out for.
To learn more from our oncology coverage and get a heads up on our latest analysis, commentary, and a global expert interview from a CAR T cell therapy specialist, subscribers can log-in or you can click to gain access to BSB Premium Content.
On their blog earlier this month, the Broad Institute posted a nice piece wittily entitled, “Opinionome: What will be the next big –ome?”
It included a chart exploring the main -omes and -omics, as well as suggestions from experts on what they saw as the next hot thing in this space.
An interesting thing that stood out to me in this timely piece was the complete and utter absence of the glycome and glycomics, which would be my answer to their provocative question – maybe not necessarily as the most hyped one – but certainly as a very impactful one.
While in Copenhagen for ESMO, we took some time out to meet with a leading global expert in the obscure field of glycomics and had the pleasure of hearing what he had to say about this exciting field of research.
The research may impact not only our knowledge about how cancer progresses, but also how it can be used to design and devise better therapeutics, including CAR T cell therapies. The answers we heard may therefore surprise.
To gain more insights, Subscribers can log in…